Bilateral Rhomboid Intercostal Block for Perioperative Analgesia in Patients Undergoing Bilateral Reduction Mammoplasty

Launched by ZAGAZIG UNIVERSITY · Jan 25, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new method to help manage pain for women undergoing bilateral reduction mammoplasty, which is a common surgery to reduce breast size. The goal is to find a safer and more effective way to provide pain relief after the surgery, compared to traditional methods that often involve opioids, which can have unwanted side effects. The researchers are looking at a technique called the bilateral rhomboid intercostal block, which aims to reduce pain without the complications associated with other regional anesthesia methods.

To participate in this trial, women aged 18 to 65 with a body mass index (BMI) of 35 or less, and who are scheduled for elective breast reduction surgery, may be eligible. However, some individuals are not suitable for this study, including those with certain medical conditions or those taking specific medications. Participants can expect to receive the new pain relief technique during their surgery and will be monitored for its effectiveness and safety. Overall, this trial seeks to improve the comfort and recovery experience for patients undergoing this type of surgery.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patient acceptance.
• • Age 18-65 years old.
• • BMI ≤ 35 kg/m2
• • ASA I - II.
• • Elective bilateral reduction mammoplasty surgery under general anesthesia.
• • Duration of surgery within five hours
• Exclusion Criteria:
• • Patients on anti-platelet, anticoagulant, or B blocker drugs.
• • Patients with acute decompensated heart failure, hypertension, heart block, coronary disease, Asthma
• • History of allergy to the local anesthetics (LA) agents used in this study,
• • Skin lesion at the needle insertion site,
• • Those with bleeding disorders, sepsis, liver disease, psychiatric disorders, and pregnancy.